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Mouse models that recapitulate the full phenotypic
spectrum of a psychiatric disorder, such as schizo-
phrenia, are impossible. However, a more piecemeal
recreation of phenotypic components is feasible and
promises to harness the power of animalmodels using
approaches that are either off limits or confounded by
drug treatment in humans. In that context, animal
models will have a central and indispensable role in
the process of discovering the causes of psychiatric
disorders and generating novel, mechanism-based
treatments. Here, we discuss current approaches
used to generate animal models of psychiatric disor-
ders, address the different components of these disor-
ders that can be modeled in animals, and describe
currently available analytical tools. We also discuss
accumulating empirical data and take an in-depth
look at what we believe to be the future of animal
modelsmade possible by recent advances in psychiat-
ric genetics.
Introduction
Eradicating the pain and suffering caused by mental
illnesses depends on discovering their causes and using
this knowledge to generate and screen mechanism-
based treatments and, ultimately, for prevention. Animal
models will have an indispensable role in this process.
What remains a critical challenge, however, is harness-
ing such model organisms to understand and manipu-
late predisposing causal factors underlying uniquely
human disorders. In this review, we describe the differ-
ent components of psychiatric disorders that may be
modeled in animals, we discuss the strengths and weak-
nesses of current approaches used to generate these
models, and we take a more in-depth look at what we
believe to be the future of animal models made possible
by advances in psychiatric and molecular genetics. For
this reason, we restrict our discussion mainly to rodent,
especially mouse, models that are amenable to genetic
manipulation. For the sake of clarity and simplicity, we
focus primarily on animal models of schizophrenia be-
cause of the recent advances in schizophrenia genetics
and the multitude of rodent models that are available.
However, our discussion is, in principle, relevant to
psychiatric disorders in general. For a more detailed
description of schizophrenia, see the review in this issue
of Neuron by Ross et al. (2006).
*Correspondence: jag90@columbia.eduCan Mouse Models of ‘‘Uniquely Human Disorders’’
Be Valid?
Generating bona fide mouse models for schizophrenia
and most human psychiatric disorders is complicated
by several empirical and theoretical reasons. The struc-
tural variation and functional divergence apparent dur-
ing hominid brain evolution reflects the orchestration
of genetic networks (Carroll, 2003) and is likely the result
of changes in the spatiotemporal expression patterns of
regulatory genes. Therefore, when modeling a suscepti-
bility gene in mice, we need to consider the possibility
that this gene is ‘‘used’’ differently in the unique contexts
of the human and mouse brains. A mutation in such
a gene may, thus, affect brain function or behavior in
the two species in a dissimilar fashion. The validation
and analysis of animal models is further complicated
by the uncertainty regarding the actual clinical features
of the human disorder and its diagnostic criteria. Con-
siderable heterogeneity exists among the symptoms of
individuals sharing a common diagnosis, as well as sub-
stantial overlap between symptoms of individuals with
different diagnoses (Taylor, 1992). Finally, in comparison
to neurodegenerative diseases like Alzheimer’s disease
or amyotrophic lateral sclerosis, where there is a well-
defined neuropathology, neuropathological markers are
not readily apparent in most psychiatric disorders,
thus further complicating the validation and analysis of
animal models. These limitations define the difficulties
we face, argue for a more piecemeal recreation of the
disorder’s components, and highlight the need for a hier-
archical approach to their validation. In that respect, the
validity of any animal model will depend on the exact
syndromic component the model is attempting to cap-
ture and the ultimate goal of the model (Geyer and Mog-
haddam, 2002; Robbins, 2004). Moreover, the utility of
any animal model will critically depend on the experi-
mental level of analysis, with a multilevel approach
more likely to identify novel features and allow their
further scrutiny.
If Only They Could Talk: Multilevel Analysis
of Mouse Models
Traditionally, animal models of psychiatric disorders are
analyzed through behavioral assays. Skepticism toward
these animal models arose from their obvious inability to
convincingly model hallmark features of human psychi-
atric disorders, such as delusions, hallucinations, or de-
pression. It is important to emphasize, however, that
mechanistic insights into the nature of the deficit under
investigation cannot be achieved by behavioral assess-
ment alone. Rather, a combined approach that begins at
the behavioral level and culminates at the cellular and
molecular levels is needed. Whatever the level of analy-
sis, it is still necessary to choose the appropriate pheno-
typic endpoints to serve as the dependent measures.
Since we are unlikely to capture the entire clinical
syndrome in an animal model, focus has shifted onto
individual behavioral, physiological, anatomical, or bio-
chemical endpoints. These endpoints are conceptual-
ized by the notion of the endophenotype: heritable
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of pathophysiological processes more proximal to par-
ticular sets of predisposing genes than the actual clini-
cal diagnosis (Gottesman and Gould, 2003). These
discrete endpoints are more amenable to model in ani-
mals than the fully expressed clinical manifestation of
a psychiatric disorder. They thus provide a more effec-
tive approach to identifying neurobiological underpin-
nings of human psychopathology.
Behavioral Level Approaches
In schizophrenia, different symptom types and disease
endophenotypes can be modeled with varying degrees
of validity (Table 1).
Modeling Positive and Negative Symptoms
Finding animal correlates of the positive symptoms of
schizophrenia (symptoms ‘‘added’’ to the normal expe-
rience, such as paranoid delusions, hallucinations, and
disordered speech and thinking) is obviously challeng-
ing. Nevertheless, hyperactivity in response to stress
or novelty and hypersensitivity to psychostimulants
have been suggested as useful correlates that can be
modeled in rodents and have been extensively used
in the validation and assessment of pharmacological
models (Geyer and Moghaddam, 2002). Less exten-
sively modeled are the negative symptoms (symptoms
‘‘subtracted’’ from the normal experience, such as
blunted emotional expression, low motivation, and so-
cial withdrawal), which contribute significantly to poor
functional outcome. These symptoms represent a signif-
icant portion of the psychopathology in major depres-
sion and, considering the substantial comorbidity be-
tween schizophrenia and depression, many of these
deficits may be secondary symptoms in schizophrenia
(Ellenbroek and Cools, 2000). Impaired social interac-
tions in animals are often used to model negative symp-
toms of schizophrenia, but the validity of this approach
is questionable (see below). Another negative symptom
often modeled is anhedonia (loss of pleasure in once
pleasurable activities), which is assessed by changes
in the reinforcing value of drugs of abuse or natural
rewards (Nestler et al., 2002). Anhedonia, however, is
more common to depression and has not been exploited
to discriminate between primary and secondary symp-
toms in animal models of schizophrenia. A detailed
description of approaches used to model depression
in mice that may be useful in modeling negative symp-
toms in schizophrenia is provided in an excellent review
by Cryan and Holmes (2005).
Modeling Cognitive Deficits
In addition to positive and negative symptoms, it has be-
come increasingly clear that morbidity in schizophrenia
is seriously affected by cognitive deficits, especially in
tasks that require executive function, working memory,
or attention (Green et al., 2000; Green and Nuechterlein,
2004). Despite their complexity, these cognitive pro-
cesses are not uniquely human and can be directly
assessed in animals.
Attention, working memory, and executive function
are frequently impaired in patients with schizophrenia,
irrespective of their level of general intelligence; exist
prior to or at the onset of the illness; and persist during
both active and remitted phases and during treatment
with antipsychotic drugs (Cannon et al., 2000; Elvevag
and Goldberg, 2000). They are also affected in a portionof their nonschizophrenic, first-degree relatives (Can-
non et al., 1994, 2000; Saykin et al., 1994). Based on
these and other observations, it has been suggested
that problems in these cognitive domains lie at the
very core of the disorder (Elvevag and Goldberg, 2000;
Green and Nuechterlein, 2004). However, within-patient
heterogeneity in neurocognitive performance and the
existence of some patients with apparently normal cog-
nitive performance has been noted in some studies
(Brewer et al., 2005; Kremen et al., 2000; Palmer et al.,
1997). Importantly, the National Institute of Mental
Health (NIMH) has recently established the Measure-
ments and Treatment Research to Improve Cognition
in Schizophrenia (MATRICS) initiative to facilitate the
development of new drugs for the cognitive deficits of
the disorder. This effort highlights the critical need for
robust preclinical assays of cognitive function that
more closely relate to neuropsychological tests in order
to facilitate translational research (Hagan and Jones,
2005; Jentsch, 2003).
Modeling Attention Deficits
The concept of attention is multifaceted and includes
the allocation of psychological resources to a specific
stimulus or task and can be reflexive or deliberate (Colby
and Goldberg, 1999). Preattentive processes tend to
be automatic and rapid and to operate outside of con-
scious awareness, whereas deliberate attentional pro-
cesses have limited resources, are effortful, and operate
more slowly. A common measure of preattentive pro-
cessing is prepulse inhibition (PPI; Table 2 and
Figure 1A) in which a brief, low-intensity acoustic stimu-
lus (the prepulse) inhibits the reflex caused by a loud
stimulus, and it has been discussed extensively in the
literature (Geyer, 2006; Geyer et al., 2001; Swerdlow
et al., 2001). This paradigm is widely used because the
assays can be administered to animals with relative
ease and in a fashion almost identical to humans.
In clinical populations, controlled attentional function
is often assessed using a continuous performance task
(CPT) (Riccio et al., 2002), which includes measures of
vigilance, response inhibition, and signal detection.
Subjects are shown a series of letters and are instructed
to respond to a rare target, like the letter ‘‘X,’’ and to
withhold responding to all other letters. In a complemen-
tary version that may be more sensitive to prefrontal
function (Javitt et al., 2000), the AX-CPT, subjects
Table 1. Some Animal Correlates of Schizophrenia Symptoms
Symptom
Type Clinical Manifestation Preclinical Model
Positive Psychomotor agitation Hyperlocomotion in response
to novelty or stress
Psychostimulant
supersensitivity
Enhanced locomotor response
to psychostimulants
Negative Social withdrawal Decreased interactions with
conspecifics
Anhedonia Decreased reinforcing
properties of drugs of abuse
and natural rewards
Cognitive Memory deficits Delayed nonmatch to sample
tasks, serial odor span
Attentional deficits Latent inhibition, 5-choice
serial reaction time tasks
Executive dysfunction Attentional set-shifting tasks
Review
181Table 2. A Sample of Rodent Cognitive Tasks that Map Onto Cognitive Domains Frequently Dysfunctional in Schizophrenia
Psycholgical
Domain Task
Measured
Constructs
Neuroanatomical
Substrates Description
Variable
Parameters Confounds
Attentional Latent
inhibition
Sustained
attention/
associability
Cortical,
hippocampal,
and striatal
circuits
Exposure to a
neutral cue
retards
subsequent
association of
that cue with an
unconditioned
stimulus
Sensory modality
of cue (visual or
auditory),
number of initial
exposures,
nature of US
(reward versus
shock)
The extent of
exposure to the
initial context in
which the cue is
present can
effect the level of
latent inhibition
5-choice
serial reaction
time task
Sustained
attention,
vigilance
Frontal and
parietal cortex,
striatal circuits
Subject monitors
an array of target
locations and
must detect and
respond to them
as they become
illuminated
Frequency,
number, and
duration of visual
stimuli, presence
of distracters
Orientation of the
rodent within the
chamber may
obscure whether
it is inattentive or
if targets are
outside its field of
vision
Memory Delayed
nonmatch to
sample
Working
memory
Prefrontal cortical
circuitry
Subject is given a
sample location
or stimulus, then
following a delay
is exposed to the
original sample
plus a nonmatch
Number of target
locations,
retention interval,
intertrial interval,
apparatus (T
maze, radial arm
maze, water
maze, etc.)
Use of intra- versus
extramaze cues,
olfactory trails,
and cryptic
strategies like
body position in
some operant
tasks
Radial arm
maze
Working memory,
spatial span
capacity
Prefrontal cortical,
hippocampal,
and striatal
circuits
Subject is given a
sample of four
baited arms, then
after a delay must
forage in the
remaining four
arms and avoid
the previously
baited arms
Delay (minutes to
hours), number of
baited arms,
variable or fixed
location of baited
arms across
trials
Overtraining, use of
olfactory trails,
motivation to
engage in task
Serial odor
span
Episodic-like
memory,
nonspatial span
capacity
Hippocampus, but
not sufficiently
characterized
Subject is
presented with
a series of odors,
then during
a probe trial must
determine which
of a sample pair
of odors comes
earlier or later in
the series
Number of stimuli
and the time
between serial
presentations,
the temporal
separation of
sample pairs
during probe
trial, spatial or
nonspatial
components
The encoding and
relative strengths
of memory traces
for particular
orders,
nonspecific
deficits in odor
recognition and
discrimination
Executive
Function
Attentional set
shifting
Behavioral
flexibility/
problem solving
Medial prefrontal
and orbitofrontal
cortex
Subject learns a
reward
association with
a cue in one
stimulus
dimension (e.g.,
visual), then must
switch to another
dimension (e.g.,
olfactory)
Order of presented
dimensions,
number of
correct
responses
needed to
advance to next
phase, pre-
exposure to
stimuli
Strengths of
different stimulus
associations
from different
sensory
modalitiesmust only respond in the appropriate context, when the
target is preceded by an ‘‘A’’ and not a ‘‘B.’’ An operant-
based rodent analog, the 5-choice serial reaction time
task (5-CSRT; see Table 2), has been developed and
extensively validated by the common neural circuits
and neurochemical modulation shared across species
(Chudasama and Robbins, 2004). This task requires
the animal to monitor, detect, and respond with a nose
poke to brief visual targets that are presented at one
end of an operant chamber (Table 2 and Figure 1B).
The animal must also learn to resist responding at inap-
propriate times, and thus measures of response control,inhibition, and impulsivity can similarly be assessed.
Although this task was originally designed for rats, it is
now used for mice as well but requires months of train-
ing to obtain a sufficient level of performance. Neverthe-
less, by manipulating task parameters such as the
duration and frequency of the targets and the time be-
tween target presentations, the complex cognitive
processes that contribute to performance can carefully
be parsed.
Another widely used measure of ‘‘attentional’’ func-
tioning in animal models of schizophrenia is latent in-
hibition (LI) (Table 2), and this paradigm has also been
Neuron
182Figure 1. Behavioral Tasks Commonly Used
in Rodents
(A) Prepulse inhibition (PPI) is often used to
measure sensorimotor gating in humans and
animals. In response to a loud noise, the sub-
ject exhibits a quantifiable, reflexive startle re-
sponse. If, however, a brief, low-intensity
acoustic prepulse precedes the loud noise,
the startle response is diminished. The mag-
nitude of change is expressed as percent
PPI, with smaller percent changes thought
to reflect deficits in sensorimotor gating.
(B) Operant chambers may be used to assess
a wide array of cognitive functions in rodents,
including working memory and attention. One
of the most well-developed tasks relevant to
many psychiatric disorders is the 5-choice
serial reaction time task (5-CSRT). This task
requires the subject to monitor, detect, and
respond to brief flashes of light. The interval
between target flashes and the duration of the target can be varied to change the difficulty of the task. In addition to attention, such tasks
can measure vigilance, impulsivity, and response control.
(C) Examples of behavioral tasks in relation to the relative dependence on frontocortical (PFC) versus hippocampal (HPC) regions. In general, the
longer the retention interval of information, the less the frontal cortex is challenged and the more the hippocampus is recruited. This is only an
approximation, and there are no clear cutoffs between different psychological processes or forms of memory. The engagement of different brain
regions and types of memory probed depend on the exact task parameters and contingencies, and different mazes may be used interchange-
ably. We provide only one example of how each may be used. Behavioral flexibility is a form of executive function and measures the ability to
discriminate between and associate one stimulus dimension (e.g., color) with reward, then shift the association to another stimulus dimension
(e.g., texture). Spatial working memory performance measures the ability to transiently remember information to guide behavior and can be
indirectly probed by forcing a run in a T maze (red arm) and after a variable delay (e.g., 5–30 s), allowing access to both the correct, ‘‘nonmatch’’
(green) and incorrect arm (red). Short-term spatial memory can also be assessed by the ability to remember the location of four open arms that
change day to day in a radial arm maze and after a variable delay (e.g., 30 min to 2 hr) forage for reward in the previously unvisited arms. Long-
term reference memory can be measured by the ability to remember the location of a hidden platform in a fixed location of the Morris water maze
after 24 hr, 1 week, or longer since the last training session.extensively reviewed (Escobar et al., 2002; Gray and
Snowden, 2005; Lubow, 2005). Briefly, when a novel
stimulus or cue is presented repeatedly without any
consequence, subsequent association of that cue with
an unconditioned stimulus is impaired. Thus, it takes
longer to learn that a light signals the availability of
food when the light was previously presented alone.
There is debate about what the actual constructs under-
lying this phenomenon are, whether it is an inability to
disengage attention to irrelevant stimuli or to form asso-
ciations between the cue and the context in which it
is presented. Nevertheless, it is important to note that
one major advantage of this phenomenon is that im-
paired LI leads to an enhancement of learning the stim-
ulus association and thus cannot be explained by
general performance deficits. Moreover, like PPI, it is
relatively high throughput compared to the 5-CSRT
and can be readily implemented in mice.
Modeling Memory Deficits
Schizophrenia patients display various forms of memory
deficits including impaired working and episodic mem-
ory. Working memory is usually defined as the ability
to maintain and manipulate information transiently in
the service of other cognitive processes to guide behav-
ior (Baddeley, 1992). Working memory deficits in schizo-
phrenia were first directly characterized using a visual
delayed response task (Park and Holzman, 1992). In
this test, subjects are asked to fixate their gaze at a cen-
tral point while a target is flashed at a fixed location
within their visual field. They must continue fixating until
the end of a delay, at which point they must shift their
gaze to the location of target presentation. More re-
cently, tests that manipulate working memory load (theamount of information held ‘‘online’’) and that require
manipulation of this information have also been used.
There are numerous working memory tasks employed
in animals, and their validity and relationship to each
other as well as common problems in their implementa-
tion have recently been reviewed (Castner et al., 2000;
Dudchenko, 2004). One common task that bears resem-
blance to the delayed response task is the delayed
nonmatch to position (DNMTP) task, which can be ad-
ministered in an operant chamber or maze (see Table 2
and Figure 1C). Initially, during a ‘‘sample’’ phase, the
subject is exposed to a lever, visual target, or arm in
a maze. Then, after a variable delay, in the ‘‘choice’’
phase the subject must select between the original
sample (the ‘‘match’’) and the target (the ‘‘nonmatch’’).
The implementation of this task varies widely between
laboratories, most notably in the time between the sam-
ple and choice phases and in between individual trials.
In humans, working memory spans mere seconds, but
many animal studies require the retention of information
over substantially longer periods of time.
Alternative approaches to working memory that ex-
ploit the animal’s natural tendency to forage are also
used and can require less training than operant-based
tasks. The same general strategy can be used in either
the holeboard discrimination (Kuc et al., 2006) or radial
arm maze tasks (Floresco et al., 1997). In the holeboard
task, the location of a limited number of food rewards
stays constant within 16 choice holes of an open field,
and the number of times the subject returns to previ-
ously visited and never-baited holes is recorded. Simi-
larly, in a version of the radial arm maze (see Figure 1C),
the subject is given a sample phase of four baited arms
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baited when given access to all eight arms.
In addition to working memory deficits, schizophrenia
patients exhibit marked impairments in episodic mem-
ory (Aleman et al., 1999), the ability to recall the time
and place of past events (‘‘what,’’ ‘‘when,’’ and ‘‘where’’).
Whether nonhuman animals have episodic-like memo-
ries is the subject of increasing debate (Clayton et al.,
2003; Hampton and Schwartz, 2004), but the presence
of long-term, declarative-like memory is not controver-
sial. A common measure of short-term episodic memory
in clinical studies is the ability to remember a list of
words. After a delay of minutes or a day, subjects are
asked to either freely recall the words, are given some
of the original words and asked to recall the others, or
are asked to identify which words in a new list were pres-
ent in the original. Schizophrenia subjects are most
impaired in free recall, and this is thought to result
from reduced connectivity of parahippocampal regions
(Talamini et al., 2005). In one relevant rodent task (Table
2), a ‘‘list’’ of discrete odors is presented in a serial
manner separated by minutes. Then, during probe trials,
two odors are presented and the subject must select the
odor that came either earlier or later in the series.
Successful performance in this task depends on the
hippocampus and is independent of spatial cues or rec-
ognition (Fortin et al., 2002). Other tasks that have epi-
sodic-like components involve remembering the time
and location of specific food rewards in a radial arm
maze (Babb and Crystal, 2006) or prospective and retro-
spective information in a cross maze (Ferbinteanu and
Shapiro, 2003) (see Figure 1C for maze configurations).
This avenue of memory assessment remains relatively
unexplored in animal models of psychiatric disorders
but offers a novel addition to traditional tests of hippo-
campal function and may have more clinical relevance.
Modeling Executive Function Deficits
Functional integrity of the prefrontal cortex is particu-
larly compromised in schizophrenia and can manifest
as deficits in executive functions. These are typically
seen as ‘‘higher-order’’ cognitive processes that play
a supervisory or controlling role over several cognitive
domains. They can be related to response control, inhi-
bition, rule switching, planning, problem solving, and
general cognitive flexibility. A traditional measure of
executive function in patients is the Wisconsin Card
Sorting Task (WCST). In this test, subjects are presented
with a deck of cards that vary by the type (e.g., circles,
squares, or triangles), the number, or the color of the
shapes shown. The subject must sort the cards based
on one stimulus dimension without knowing which one
and use only feedback from the experimenter. Once
the rule is acquired, the experimenter changes the rule
without notifying the subject. A rodent assay of execu-
tive function, attentional set shifting (Birrell and Brown,
2000) (Table 2), has gained rapid popularity due to the
relative ease of its implementation. In this task, subjects
are trained to dig in bowls for food rewards that are
paired with different digging media or odorants. During
the first phase, the subject must learn that food is asso-
ciated with particular odorants irrespective of digging
media. In the second phase, the subject must then learn
that food is associated with particular digging media ir-
respective of odorants, an extradimensional shift. Theadvantage of this task is that it is very similar to the
WCST and requires only 1 day of testing, but it may
take hours for a single mouse to complete. The order
of associated dimensions can present an additional
problem, given that some sensory modalities, like
odor, may be more easily associated with food than
others.
Ethological Approaches
Debates concerning the best methods in assessing an-
imal behavior began with the founding of ethology a cen-
tury ago, and they continue today (Gerlai and Clayton,
1999; Sarter and Berntson, 1999). Recently, there has
been a revival of interest in ethological approaches, es-
pecially in the assessment of animal models of psychiat-
ric disorders (Crabbe and Morris, 2004; Tecott and Nes-
tler, 2004). The rationale is that monitoring spontaneous
behaviors (such as foraging strategies, social organiza-
tion, and diurnal patterns of activity) in ‘‘naturalistic’’ set-
tings can reveal deficits that would not be apparent in
more traditional laboratory tasks. Practical approxima-
tions to natural environments are often performed in lab-
oratory conditions that are sufficiently similar so that the
animal could behave as if it were in its natural, ancestral
habitat. Ethological approaches have not been widely
used or validated in research of animal models of human
psychiatric disorders. One of the few uses of ‘‘ethologi-
cal’’ approaches in psychiatric research are the smaller
scale studies by Waddington and colleagues that in-
volve sampling, over an extended time frame, of individ-
ual elements of behavior in the mouse repertoire, such
as sniffing, locomotion, rearing behavior, sifting, groom-
ing, chewing, jumping, and stillness (Waddington et al.,
2005; O’Tuathaigh et al., 2006). These studies may pro-
vide useful insights when examining, for example, how
a given strain, mutant in a susceptibility gene, affects
behavior over the prolonged course of interaction with
the environment and under various pharmacological
challenges. It is worth pointing out here that human
neuropsychological tests, designed to probe specific
psychological processes, are not in any way ethological
in the sense that they do not consider behaviors in either
our ancestral or modern environments. They nonethe-
less have predictive power over functional outcome in
the real world. Thus, ethological approaches may com-
plement, but not replace, current measures of animal
cognition that have arisen from the merger of experi-
mental and clinical neuropsychology.
Some General Considerations Regarding Choice,
Implementation, and Interpretation of Behavioral
Tests
Ideally, the most important criterion in choosing tests
appropriate to model a clinical syndrome and interpret-
ing their results is the conservation of neural circuitry un-
derlying a given behavior (Brown and Bowman, 2002;
Robbins, 1998). It is important to emphasize, however,
that the underlying neural circuitry for the behaviors de-
scribed above are relatively complex and often not well
characterized, and therefore it is not always possible to
select appropriate behavioral tests that allow meaning-
ful interpretations. Assays of social interactions and
PPI provide relevant examples. Social and mating be-
havior in mice depends, to a large extent, on olfaction.
Manipulations, whether pharmacological or genetic,
that alter these behaviors may exert their effects through
Neuron
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clinical deficits. In fact, social withdrawal in patients
may arise from general anhedonia, anxiety, and/or so-
cial cognitive deficits (Green et al., 2005). Thus, without
knowing the underlying neuronal circuitry of the behav-
ior or symptom and the causes of any dysfunction, the
animal model is left simply with superficial similarity to
the disease (Robbins, 1998). This limits the immediate
utility of ethological approaches that monitor the social
behavior of rodents as a model of human social dysfunc-
tion. PPI is one of the best, if not the best, characterized
behavioral trait at the neural systems level and is modu-
lated by complex neural circuits spanning a large array
of brain regions (Swerdlow et al., 2001). The underlying
circuitry is so complex, however, that it is not always
clear, in the absence of corroborating evidence, whether
the deficits are due to pathophysiological mechanisms
shared with schizophrenia. The same limitations will cer-
tainly apply to other behavioral assays, and because of
this, a well-defined framework for assessing the rele-
vance of a given behavioral paradigm to schizophrenia
(or any other psychiatric disorder) based on the underly-
ing neural circuits is not yet available. Until this is
accomplished, an emphasis needs to be placed on con-
verging evidence from multiple tests designed to mea-
sure the same physiological process, psychological
construct, or affective state and on judiciously manipu-
lating task contingencies within a single test to control
for confounding sensory or motor deficits. For example,
working memory performance may be assessed in a Y
maze, T maze, cross maze, radial arm maze, and even
a Morris water maze (see Figure 1C). These tasks will
vary in the amount of training required, the level of diffi-
culty, and whether they are appetitively or aversively
motivated. Moreover, even for a single task, the exact
task parameters will determine the extent to which dif-
ferent brain regions are engaged. If working memory is
truly affected, however, deficits should not be restricted
to one particular task. The disadvantage with such prac-
tices is that they are time consuming, labor intensive,
and require sufficient knowledge of experimental psy-
chology and animal behavior for appropriate analysis
and interpretation of findings.
Another consideration has to do with whether a stan-
dard set of tests should be performed in the initial stages
of characterizing an animal model of a psychiatric disor-
der. Indeed, development of a consensus, standardized
battery of tests has been proposed as a remedy to the
lack of standardized procedures for measuring specific
behaviors, an issue that has frustrated many and
impeded crossvalidation across studies (Floresco et al.,
2005; Tecott and Nestler, 2004). Even if such a consensus
battery of tests is achieved, this does not guarantee
a solution, because behavioral tasks conducted under
identical protocols can still yield conflicting results de-
pending on the laboratory environment. This is espe-
cially true for small effect outcomes (Crabbe et al.,
1999; Wahlsten et al., 2003), which are likely when ma-
nipulating a single predisposing allele in genetic animal
models. One proposed solution to this problem is the
development of automated and high-throughput sys-
tems to track a suite of behaviors and then use informa-
tion technologies to identify behavioral repertoires that
rely on specific neural circuits and respond to selectivepharmacological agents (Tecott and Nestler, 2004).
These approaches offer obvious advantages in screen-
ing candidate therapeutic compounds and in large-
scale mutagenesis screens. As noted by Crabbe and
Morris (2004), however, whether data collected auto-
matically are less variable than data collected manually
has not been established experimentally. In addition, it
is hard, at present, to envision how some of the more so-
phisticated schizophrenia-relevant cognitive tests out-
lined above can be efficiently adapted to fit within an
automated, high-throughput context. Apart from the
technical issues, batteries of tests or batteries of analy-
ses are, for the most part, nonhypothesis driven and
‘‘agnostic’’ as to the effect of a given experimental ma-
nipulation. This leads to the need of statistical correc-
tions for multiple comparisons, especially when there
are multiple dependent measures for each behavioral
assay, but these are rarely performed in behavioral
screens. Despite these caveats, in the case where the
biology of a gene is uncertain, standardized batteries
of tests may be the only option and are not without merit.
Indeed, they can offer a starting point and general guid-
ance toward potentially affected behavioral domains.
Any significant effects, however, need to be systemati-
cally followed up in a direct and rigorous manner with
more specific tests.
An alternative and preferable approach to phenotyp-
ing an animal model, especially genetic models of sus-
ceptibility genes, is a hypothesis-driven approach that
takes into consideration the biology and function of
the gene in question (such as expression patterns, con-
tribution of genetic variants to specific endophenotypes
in patients and healthy volunteers). Thus, although many
behavioral tests may be time consuming, specific hy-
potheses about what neural circuits and psychological
constructs are likely affected will direct the selection of
initial tests. Finally, it is worth pointing out here that,
due to recent advances in human genetics and the gen-
eration of an increasing number of reliable etiological
models, the role of behavioral assays is likely to shift,
over the next several years, from primarily model valida-
tion to providing mechanistic insights into the nature of
the genetic factors under investigation. In this context,
insights will be provided by a combined approach that
includes not only behavioral assessment, but also sys-
tems, cellular, and molecular level approaches. These
latter approaches, which are only briefly outlined below
due to space constraints, hold great promise for novel
breakthroughs in psychiatric research.
Systems Level Approaches
Approaches at this level are feasible because, despite
the extensive neuroanatomical divergence between
mice and humans, particularly the considerable expan-
sion of the frontal cortex (which is especially affected
in schizophrenia), the basic layout of fundamental neural
circuits between cortex and well-conserved, subcortical
structures remains largely intact. The imminent avail-
ability of etiological models combined with the advent
of rodent neuroimaging and recording technologies
will greatly facilitate the identification of brain regions
affected by a given etiological factor and will also allow
delineating the interactions among regions affected in
dysfunctional states. For example, several prominent
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a disconnection between frontocortical and temporal
limbic regions of the brain (Meyer-Lindenberg et al.,
2005). This can, in principle, be tested using in vivo
recordings combined with direct neuronal stimulation
of inputs to assess how different brain regions drive
the activity of others. Another promising avenue is the
use of simultaneous multiunit recordings from inter-
connected brain regions in awake-behaving animals
(Jones and Wilson, 2005; Siapas et al., 2005). This would
allow the disentanglement of proposed desynchrony of
neural oscillations among brain regions of patients as
they perform cognitive tasks (Green and Nuechterlein,
1999).
Cellular and Molecular Level Approaches
Approaches at this level are the most upstream from the
observed clinical psychopathology, but they have two
important advantages. First, molecular and cellular
functions of a gene are more likely to be evolutionarily
conserved compared to any behavioral outcomes the
gene may influence. Second, it is conceivable that the
‘‘closer’’ one probes to the primary deficit, the less likely
it is that downstream compensatory mechanisms come
into play, and the more likely that any resulting func-
tional consequences will be detectable. Therefore,
more reductionistic measures could be more sensitive
in detecting underlying dysfunctions compared to be-
havioral outcomes that are multifaceted and perhaps
subtler due to the deployment of compensatory mecha-
nisms. Cellular and molecular level approaches can be
used to identify the cellular and synaptic substrate(s) un-
derlying the consequences of specific genetic, pharma-
cological, or neurodevelopmental disruptions or to
identify (in a high-throughput fashion) changes in gene
expression, protein levels, or posttranslational modifi-
cations. These latter approaches, in particular, hold
great promise for identification of individual genes,
gene pathways, and cellular processes that either serve
as direct targets or interact with the disrupted pathways
to increase susceptibility to a given psychiatric disorder
(Anholt et al., 2003; Mirnics et al., 2003, 2005). Indeed,
recent work in genetic mouse models suggests that
some changes in gene expression induced by a mutation
could be adaptive in nature and could reduce the pene-
trance of the primary mutation (Paterlini et al., 2005). As
such, identifying compensatory changes in the brains of
mouse models can point to novel, endogenous ‘‘strate-
gies’’ developed by the brain to cope with introduced
deficits. The involvement of these compensatory ge-
netic pathways can be verified in follow-up human
genetic studies and exploited as targets for novel
treatments.
Deconstructing Schizophrenia in a Model Organism
To date, animal models of psychiatric disorders have
been developed for different goals and have implicitly
or explicitly modeled different aspects of the disorder
in question. Models of pathophysiology attempt to ad-
dress the most proximal brain dysfunction that could
produce the clinically observed psychopathology.
Models that attempt to recapitulate the processes that
lead to the pathophysiology of a disorder are models
of pathogenesis. Finally, models designed to confirmor identify experimentally probable causal factors in
the development of the disorder are etiological models.
These have been the most difficult models to produce
because very little was known about the root causes
of many psychiatric disorders. Recent advances in our
understanding of the relevant genetic and environmen-
tal risk factors, however, have increased the likelihood
of developing such models.
Models of Pathophysiology
These models typically rely on the assumption that, be-
cause a psychoactive drug produces a psychopathology
similar to that seen in individuals with a certain psychiat-
ric disorder, the neurotransmitter system affected by the
drug is dysfunctional in the disorder (Svenningsson
et al., 2003; see the review in this issue of Neuron by
Ross et al. [2006]). Thus, pathophysiological animal
models are usually pharmacological, but, as described
below, genetic mouse models have also provided useful
insights (Gainetdinov et al., 1999; Glickstein et al., 2002;
Kellendonk et al., 2006; Mohn et al., 1999). Although ad-
ditional neurochemical systems have been implicated,
we will focus on dopamine- and glutamate-based
models because these are the most extensively studied.
Animal Models of Dopaminergic Dysregulation
The dopamine hypothesis of schizophrenia has been re-
viewed extensively (Kapur, 2003). Simply, this hypothe-
sis postulates excessive dopaminergic transmission in
schizophrenia, although the explanatory power of dopa-
mine excess is limited to positive symptoms, as it can-
not account for the prominent cognitive and negative
symptoms of schizophrenia (Davis et al., 1991). These
limitations led to several refinements and reformulations
of the dopamine theory of schizophrenia to include com-
plex reciprocal interactions between dopamine systems
leading to deficient cortical and excessive subcortical
dopamine (Deutch, 1992; Grace, 1991). A recent study
by Kellendonk et al. (2006) attempted to probe further
the basis of the reformulated dopamine hypothesis us-
ing an elegant genetic approach. Based on a number
of observations linking increased striatal dopamine D2
receptors (DRD2s) and dopaminergic transmission to
the pathophysiology of schizophrenia (Abi-Dargham
et al., 1998), these authors created a transgenic mouse
line that selectively and transiently overexpressed DRD2s
within the striatum of mice. It was found that DRD2 over-
expression in the striatum decreases dopamine turnover
and increases activation of dopamine D1 receptors
within the frontal cortex, factors known to impact work-
ing memory performance across species (Goldman-
Rakic, 1999). These transgenic mice also exhibit selec-
tive behavioral impairments in tasks dependent on the
frontal cortex. These deficits persist even after the
transgene has been switched off, indicating that it results
from excess DRD2 expression during development. In-
terestingly, despite changes in striatal DRD2 occupancy
similar to that observed in patients, these transgenic
mice were only modestly impaired cognitively, suggest-
ing that DRD2 dysfunction of the magnitude observed in
patients is not sufficient to produce severe cognitive
deficits in animal models. The work of Kellendonk et al.
(2006) highlights the importance of a circuit-based
approach to understanding the pathophysiology of psy-
chiatric disorders. In addition, because this animal
model is an extension of traditional pharmacological
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provement of current pharmacotherapies.
Animal Models of Glutamatergic Dysregulation
The glutamate hypothesis of schizophrenia has also
been reviewed extensively elsewhere (Goff and Coyle,
2001; Javitt and Zukin, 1991). This hypothesis has moti-
vated the generation of a plethora of pharmacological
models (Jentsch and Roth, 1999; Moghaddam and
Adams, 1998). Possibly one of the most important con-
tributions of these models was the reconciliation of tra-
ditional dopamine models with the mounting evidence
of reduced NMDA receptor (NMDAR) function (Jentsch
et al., 1997). In addition to pharmacological models,
genetically engineered mouse models have also been
employed to study the presumed NMDAR hypofunction
in schizophrenia. In one such model, the expression of
the obligate subunit, NR1, of the NMDAR was reduced
to 5% of endogenous levels in mice (Duman, 2002; Dun-
can et al., 2002; Mohn et al., 1999). As expected, these
mice showed reduced sensitivity to NMDAR antagonists
and demonstrated a ‘‘schizophrenia-like’’ phenotype
that included decreased social interactions and hyperlo-
comotion. Many of these abnormal behaviors were ame-
liorated with antipsychotic drug administration. How-
ever, the nature and specificity of any cognitive
deficits related to schizophrenia were not assessed.
What both dopamine and glutamate models have in
common is that they attempt to account for the most
proximal causes of the disease-associated psychopa-
thology. This allows for the generation of symptom-
based treatments that might offer the best hope for
those already diagnosed with schizophrenia (Costall
and Naylor, 1995; Coyle and Tsai, 2004; Goff and Coyle,
2001). It is questionable whether these models on their
own will provide insights into the actual causes leading
to the pathophysiological state. They may, nonetheless,
be instrumental in interpreting results obtained from
models of etiology (see below).
Models of Pathogenesis
Several lines of evidence have led to the hypothesis that
early developmental insults set the way for abnormal
brain development and the later emergence of psycho-
sis (Weinberger, 1995). At least two widely used animal
models, employing early, in utero, or postnatal perturba-
tions that interfere with normal brain maturation, ad-
dress this possibility. One model employs lesioning
the ventral hippocampus of neonatal rats, the brain re-
gion homologous to the portion of hippocampus most
affected in patients (Lipska and Weinberger, 2000).
This lesion does not produce any obvious behavioral ab-
normalities in the young pups. During adolescence,
however, several behaviors related to schizophrenia
emerge. These include increased locomotor response
to stress and novelty, supersensitivity to amphetamine
(AMPH), and PPI deficits. Many of these behaviors are
reversed with exposure to antipsychotics, and adult
lesions do not produce similar effects. Another neuro-
developmental model aims to disrupt normal brain de-
velopment in more subtle ways. In this model, the devel-
oping rodent fetus is exposed to a methylating agent at
specific time points (Moore et al., 2006). Depending on
the time window and dosage, adult rats exhibit several
neuroanatomical and behavioral abnormalities related
to schizophrenia. These include increased cortical neu-ronal density, supersensitivity to AMPH, and cognitive
deficits. Similar to the ventral hippocampal lesion
model, the supersensitivity to AMPH does not manifest
until adulthood. Because there is no evidence of similar
lesions playing a role in the development of schizophre-
nia, both models lack etiological validity, but they pro-
vide useful insights on how abnormal brain development
can lead to the characteristic postadolescent manifesta-
tion of the disorder and could facilitate generation of
novel treatments.
Models of Etiology
Environmental Models
Since the early 20th century, several environmental
causes of schizophrenia and other psychiatric disorders
have been proposed. These include obstetric complica-
tions, malnutrition, and viral exposures (Jablensky,
2003). For example, epidemiological studies show an in-
creased risk for psychosis among children exposed to
influenza and other viruses during the second trimester.
Subsequent animal models showed that if pregnant
rodent mothers are induced to mount an immune re-
sponse, the offspring grow to show behavioral abnor-
malities (Meyer et al., 2005). This is accomplished by
injecting a synthetic double-stranded RNA, polyriboino-
sinic-polyribocytidilic acid (poly[I:C]) that mimics viral
exposure and causes release of proinflammatory cyto-
kines in the pregnant mothers. The resulting behavioral
deficits in the adult offspring include impaired PPI and
cognitive performance as well as increased sensitivity
to MK801 and AMPH (Shi et al., 2003). Other animal
models have shown that viral exposure during different
developmental periods may lead to diverse psychopa-
thologies (Meyer et al., 2006), indicating that animal
models of etiology will be critical in determining how
shared environmental risk factors may give rise to
distinct psychiatric disorders.
Genetic Models
Genetic factors play a prominent role in many psychiat-
ric disorders, and numerous putative candidate genes
have been identified (Gogos and Gerber, 2006). Mouse
models of ‘‘susceptibility genes’’ identified through
human genetic studies hold tremendous promise in
understanding the function of a gene and its contribu-
tion to disease pathophysiology in the context of tracta-
ble cellular pathways, neural circuits, and behavior.
They also offer several additional, unique advantages.
For example, they allow for the identification of early
mutational effects and the study of their developmental
progression. In addition, they allow for an efficient and
thorough investigation of interactions among suscepti-
bility genes and between genes and environmental
factors, all of which underlie the complexity of psychiat-
ric disorders.
There are two predominating hypotheses regarding
the genetic architecture of complex psychiatric disor-
ders such as schizophrenia. According to the common
disease/common allele hypothesis (Pritchard and Cox,
2002), no single gene is necessary or sufficient to cause
the disease, but instead, common (R1%) variants in
more than one susceptibility gene, each contributing
a small effect, act in combinations to increase the risk
of illness. In that context, a mouse model for an individ-
ual candidate gene is unlikely to capture the entire
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(common disease/rare allele hypothesis) proposes that
complex psychiatric disorders may instead result from
the effects of many rare but penetrant variants, with sub-
stantial allelic heterogeneity at disease-causing loci.
Identification of such rare alleles, if they exist, will defi-
nitely facilitate modeling efforts, especially when highly
penetrant loss-of-function alleles are involved that can
be faithfully modeled by simple knockout mouse
models. Empirical data suggest that both modes of in-
heritance may operate for at least some risk genes.
For example, both common and rare variants were iden-
tified in two leading candidate genes, proline dehydro-
genase (PRODH) and Disrupted-in-Schizophrenia 1
(DISC1) (Gogos and Gerber, 2006). Unexpectedly, natu-
ral variants that closely mimic the human counterparts
were also identified in mouse orthologs of these two
genes, providing a unique opportunity to model the con-
sequences of the human disease variants (Gogos et al.,
1999; Koike et al., 2006). These are likely fortuitous ex-
ceptions, however, and sophisticated gene-targeting
strategies will be required to generate models for the
majority of susceptibility genes. In that respect, there
are several important factors that need to be considered
for the generation of such models and for the design and
interpretation of their analysis, and some general guide-
lines are provided below.
The Functional Significance of a Risk Allele
The most important consideration in developing etiolog-
ically valid genetic mouse models has to do with the
nature of the disease-associated genetic variants. In
the case of complex genetic disorders, the associated
variants usually have no obvious effect on protein struc-
ture (Rebbeck et al., 2004). To complicate things further,
these genetic variants may only serve as proxies for
physically linked, true risk variant(s) residing within the
identified gene or a nearby gene (linkage disequilibrium)
(Newton-Cheh and Hirschhorn, 2005). Finally, few of the
disease-associated variants are expected to be null al-
leles, and therefore it is highly unlikely that a knockout
mouse model with a global and persistent neuronal
and nonneuronal decrease in the target gene levels will
serve as an accurate model of the risk allele. These
uncertainties contribute to the challenging task of estab-
lishing causality from human genetic association
studies and mouse models. Obviously, the minimum
amount of information needed is whether the risk allele
is a hypomorph or gain of function and therefore
whether a mouse knockdown strategy or transgene-
mediated overexpression, respectively, can model it
accurately. Additional desirable information would be
whether the risk variant affects, for example, splicing
or expression in specific brain areas, cellular popula-
tions, or developmental stages.
The Effect of Pleiotropy
A related consideration has to do with the wide expres-
sion and pleiotropic effect of many targeted genes.
Given such pleiotropy and complexity, in the absence
of reliable information on the nature of the predisposing
allele, one needs to consider carefully when modeling
such genes using mouse knockout approaches which
of a large number of alternative phenotypes is a critical
link between the disease-related genetic risk variant(s)
and susceptibility to the specific psychiatric disorder.Recent results from two leading candidate genes help
illustrate some of the relevant difficulties of translating
human genetic findings into informative animal models
of predisposing genetic factors. Neuregulin-1 (NRG-1)
is a leading candidate susceptibility gene for schizo-
phrenia (Stefansson et al., 2002). Nrg-1 knockout mice,
lacking various domains of the gene, have been exten-
sively used to understand the broad deficits in neuronal
migration and neurite outgrowth, glial cell proliferation,
and cellular signaling induced by impaired Nrg-1 func-
tion (reviewed in Corfas et al. [2004]). These same mice
show, among other phenotypes, decreased expression
of NMDA receptors, impaired PPI, and deficits in LI as
well as changes in exploratory behavior and habituation
in ethologically based assays (Rimer et al., 2005; Ste-
fansson et al., 2002). The functional implications of the
NRG-1 genetic variation related to schizophrenia, how-
ever, are unclear, and a recent study on human postmor-
tem tissue seems to indicate that NRG-1 signaling may
be enhanced in some individuals with schizophrenia
(Hahn et al., 2006). Thus, although the mouse studies
summarized above provide insight into the basic func-
tion of NRG-1, whether a knockout mutation can model
the relevant clinical aspects of its genetic contribution is
arguable and the subject of ongoing investigation
(Hashimoto et al., 2004; Law et al., 2006; Petryshen
et al., 2005).
Brain-derived neurotrophic factor (BDNF) is a leading
candidate susceptibility gene for bipolar disorder, ob-
sessive-compulsive disorder, and possibly schizophre-
nia. BDNF participates in practically all aspects of brain
development, maturation, and function. The function of
this gene has been extensively studied using a variety
of constitutive as well as spatially and temporally re-
stricted knockout mice (Akbarian et al., 2002; Chourbaji
et al., 2004; Gorski et al., 2003; Kernie et al., 2000; Lyons
et al., 1999; Monteggia et al., 2004). It is unclear, how-
ever, how accurately these studies model the genetic
contribution of the gene. Indeed, recently, a primate-
specific Val66Met functional missense polymorphism
in the coding region of the BDNF gene that appears to
regulate BDNF trafficking to synaptic sites and depolar-
ization-dependent secretion has been identified. This
polymorphism was shown to modulate the risk of a num-
ber of psychiatric disorders (Geller et al., 2004; Hall et al.,
2003; Sklar et al., 2002) as well as a number of related
endophenotypes (Egan et al., 2003), and, intriguingly,
some of these studies indicated an unexpected protec-
tive effect for the Met66 variant, which causes impaired
regulated secretion of BDNF. Thus, modeling impaired
activity-induced release of BDNF using humanized
knockin mouse models would allow additional and
possibly more precise insights into the nature of the
contribution of this gene.
The Effect of Genetic Background, Environment,
and Sex
Apart from controlling for the confounding factors out-
lined above and independent of the modeling approach,
several recent findings highlight the importance of defin-
ing and controlling genetic backgrounds, environmental
variables, and sex when developing and analyzing
genetic models of psychiatric disorders (Cabib et al.,
2000; Crabbe et al., 1999; Gerlai, 1996). In particular,
the genetic background onto which a mutation is
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a mutant mouse. This may result from a nonoptimal
baseline level of behavior in wild-type control animals.
For example, different inbred strains manifest variable
levels of PPI (Dulawa and Geyer, 2000; Logue et al.,
1997; Paylor and Crawley, 1997). Among some of the
most commonly used strains, both C57BL/6 and
129Sv strains demonstrate PPI (although C57BL/6
shows reduced PPI levels compared to the 129Sv),
whereas the DBA/2 strain shows little, if any, PPI and
therefore represents an undesirable genetic back-
ground for the examination of a mutation that might re-
duce PPI. Similar background-dependent variability
has been reported in other relevant cognitive behavioral
tasks, including habituation (Dulawa and Geyer, 2000),
the Morris water maze, and fear-conditioning tasks
(Owen et al., 1997), as well as in continuous alternation
tasks (Gerlai, 1998). The effect of genetic background
is task specific, and therefore there is no ‘‘best’’ strain
that can be recommended across all behavioral tasks.
Instead, the genetic background should be chosen
based on the postulated effect of a given mutation on el-
evating or reducing the behavioral phenotype under
scrutiny (Crawley et al., 1997). Complications may also
arise from the undesirable contribution from flanking
genes derived from the ES cell donor strain (discussed
in detail by Crusio [2004]), as well as from complex func-
tional interactions between the mutation and back-
ground genes that may mask the effect of the introduced
mutation (see also below). Indeed, the recent finding
that one of the most widely used mouse strains carries
a mutation in Disc1 (Koike et al., 2006), a leading schizo-
phrenia candidate gene, underscores even further the
importance of controlling the genetic background
when modeling genes predisposing to schizophrenia
and related psychiatric disorders. In addition to genetic
background, controlling for laboratory environmental
variables is also important, especially regarding the reli-
ability and reproducibility of relatively subtle behavioral
effects. This issue is discussed in great detail in Crabbe
et al. (1999) and Wahlsten et al. (2003). Finally, experi-
mental studies of mouse models have traditionally in-
cluded exclusively male subjects, in an effort to control
for the potentially confounding hormonal effects during
the estrous cycle in females. However, given the accu-
mulating evidence for gender-specific genetic effects
on the risk and course of psychiatric diseases as well
as on the severity of their symptoms (Hafner, 2003;
Hennah et al., 2003), it is advisable that analysis be
carried in animals of both sexes.
Accumulating Empirical Data
In the past 4 years, significant advances in susceptibility
gene discovery have taken place fueled by the complete
sequencing of the human genome, the availability of
high-throughput genomic analyses, and the generation
of new analytical and bioinformatics tools. Several can-
didate susceptibility genes have been identified, each
supported by varying degrees of evidence (Gogos and
Gerber, 2006). These recent advances in gene discovery
have started bearing fruit, and the first genetic mouse
models of susceptibility genes have emerged.Constitutive or Conditional Knockout Models
For the most part, genetic mouse models have been lim-
ited to constitutive or conditional knockouts. These
models are summarized in Table 3 as well as in recent re-
views by Chen et al. (2006) and Powell and Miyakawa
(2006). Although they do not necessarily reproduce the
risk alleles and therefore have limited etiological validity,
these models should contribute to our efforts to identify
candidate genes and understand their general function,
as well as to identify the genetic pathway(s) they partic-
ipate in. In addition to the Nrg-1 knockout mice de-
scribed above, another relevant example is provided
by a conditional knockout of the gene encoding for the
calcineurin-regulatory subunit. These mice demonstrate
several schizophrenia-related phenotypes, such as def-
icits in working memory and PPI (Miyakawa et al., 2003),
and thus implicate the calcineurin-signaling pathway in
the pathogenesis or pathophysiology of schizophrenia.
Although variants in this gene have not been shown to
increase risk for schizophrenia, another gene in the
pathway (PPP3CC) has been identified as a potential
susceptibility gene (Gerber et al., 2003).
Mice deficient in the gene encoding for Akt1 provide
an additional example. A greater sensitivity to the dis-
rupting effects of AMPH on PPI was initially observed
in an Akt1-deficient mouse model (Emamian et al.,
2004). This observation, along with evidence for a
decrease in AKT1 protein levels and substrate phos-
phorylation levels in brains and lymphocytes of some
individuals with schizophrenia (Emamian et al., 2004),
implicated the AKT1 signaling pathway in the neurobiol-
ogy of schizophrenia. Subsequent analysis confirmed
an association between schizophrenia and AKT1 ge-
netic variants (Emamian et al., 2004; Schwab et al.,
2005) and also showed that AKT is a key signaling inter-
mediate downstream of DRD2, the best-established
target of antipsychotic drugs (Beaulieu et al., 2005).
Mouse Models that Mimic Putative Risk Alleles
In addition, a small number of mouse models have re-
cently appeared that closely mimic putative risk alleles
identified by human genetic studies. Although the level
of analysis of these models is in early stages, such
mouse models hold great promise for testing the general
utility of accurate genetic mouse models of psychiatric
disorders. Moreover, they will be instrumental in design-
ing an efficient framework for analyzing additional etio-
logically valid genetic mouse models that are likely to
appear in the next few years. Importantly, these models
are based on rare genetic lesions strongly linked to psy-
chiatric disorders and circumvent the uncertain nature of
some genetic association studies. They thus are more
likely to have etiological validity. Despite the fact that
these models are based on rare genetic events, they
nonetheless may help identify cellular pathways and neu-
ral circuits dysfunctional in schizophrenia in general. Em-
pirical data from these models are summarized below.
Mouse Models of the 22q11 Schizophrenia
Susceptibility Locus
22q11 microdeletions represent the first unequivocal as-
sociation between a well-defined genetic lesion and
schizophrenia at the population level, accounting for
w1%–2% of the disease in Caucasian samples (Kar-
ayiorgou et al., 1995). Notably, individual carriers of
a 1.5 Mb deletion in the q11 locus of chromosome 22
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189Table 3. Phenotypes Associated with Null Alleles of Mouse Orthologues of Some Schizophrenia Candidate Genes
Gene Mutation Phenotype References
DTNBP1 Spontaneous null allele Albinism, pulmonary fibrosis Li et al., 2003
NRG1 Heterozygous targeted null alleles Abnormal exploratory behavior and habituation,
PPI and latent inhibition deficits, reduced
NMDAR expression
Rimer et al., 2005; Stefansson
et al., 2002
RGS4 Targeted null allele Motor coordination deficits, analgesia Grillet et al., 2005
PPP3CC Conditional null allele of the
regulatory subunit
Hyperactivity, working memory deficits, PPI and
latent inhibition deficits, decreased social
interactions, MK801 hypersensitivity
Miyakawa et al., 2003
AKT1 Targeted null allele AMPH hypersensitivity Emamian et al., 2004
BDNF Various conditional or constitutive
null alleles
Hyperactivity, spatial learning and memory
deficits, associative learning deficits
Chourbaji et al., 2004; Egan et al.,
2003; Gorski et al., 2003; Kernie et al.,
2000; Lyons et al., 1999(22q11) have an w20- to 30-fold higher risk to develop
schizophrenia as compared to the general population
(Karayiorgou and Gogos, 2004). Most of the 27 known
genes located within the deleted region are expressed
in the brain in a relatively wide pattern. Results of the ge-
netic analysis performed so far suggest that 22q11 mi-
crodeletion-associated schizophrenia may have the
characteristics of a contiguous gene syndrome where
a small subset of the deleted genes (that may interact
with each other) dramatically increase disease risk (Kar-
ayiorgou and Gogos, 2004). The syntenic region of the
human 22q11 locus, which lies on mouse chromosome
16, includes nearly all human genes but in slightly differ-
ent order. The robust association between this well-de-
fined genetic lesion and the unprecedented increase in
the risk to develop schizophrenia, coupled with the con-
served arrangement of the mouse orthologs in the syn-
tenic locus, provides a unique opportunity to generate
mouse models with strong etiological validity that are
poised to offer novel insights into the neurobiology of
schizophrenia.
The 22q11 microdeletion has been modeled in the
mouse using chromosomal engineering approaches
(Paylor et al., 2001; K. Stark, A. Bagchi, H. Liu, A. Mills,
M. Karayiorgou, J.A.G., unpublished data). Paylor and
colleagues (Paylor et al., 2001) showed that mice carry-
ing a deletion that represents only a subregion of the
‘‘schizophrenia critical region’’ (Karayiorgou et al.,
1995) have deficits in PPI and associative fear memory.
In the latter case, the response of these mice suggests
that they have difficulty remembering the types of cues
associated with a complex training environment for
long (24 hr), but not short (1 hr) periods, indicating defi-
cits in hippocampal function (Abel et al., 1997; Le Pen
et al., 2000). More recent work in mice carrying a deletion
equivalent to the entire schizophrenia critical region has
identified marked cognitive impairments in working
memory tasks (W.-S. Lai, K. Stark, M. Karayiorgou,
and J.A.G., unpublished data). These observations indi-
cate that this genetic model may have excellent etiolog-
ical and face validity.
Single-gene models have also been generated for
candidate susceptibility genes from the 22q11 locus.
Among them, PRODH is a leading candidate gene (Go-
gos and Gerber, 2006) identified initially through human
genetic studies in families afflicted with schizophrenia
(Jacquet et al., 2005; Liu et al., 2002). It encodes a mito-
chondrial enzyme that metabolizes L-proline, a putativeneuromodulatory amino acid that may influence gluta-
matergic transmission (Renick et al., 1999). A Prodh
knockdown mouse strain that represents an accurate
model of the functional consequences of susceptibility
variants described for this gene (Bender et al., 2005)
has been established and shows many neurochemical
and behavioral features relevant to schizophrenia (Go-
gos et al., 1999; Paterlini et al., 2005). Specifically, Prodh
deficiency caused a significant enhancement in gluta-
mate release and synaptic transmission at CA3-CA1
synapses. Importantly, in vivo microdialysis revealed in-
creased cortical dopamine efflux in the mutant mice fol-
lowing acute, systemic AMPH administration. In con-
trast to some human studies showing increased
AMPH-induced dopamine release in the striatum of pa-
tients with schizophrenia, AMPH-induced striatal, dopa-
mine efflux was normal. Nevertheless, Prodh-deficient
mice showed hypersensitivity to the locomotor effects
of AMPH, abnormal PPI, and deficits in both hippocam-
pal and amygdala-based forms of associative learning.
When tested in a delayed-alternation task, low Prodh
activity was not associated with changes in spatial
working memory performance. However, deficits in
this task emerged in Prodh-deficient, but not wild-
type, mice upon pharmacological inhibition of Comt,
an enzyme involved in degradation of dopamine and en-
coded by a schizophrenia candidate gene also located
within the 22q11 microdeletion locus. Inhibition of
Comt activity also potentiated the effect of AMPH on
locomotor activity and induced further deficits in PPI
specifically in Prodh-deficient mice, providing the first
biological evidence for interaction between two schizo-
phrenia susceptibility genes. This interaction was also
reflected at the transcriptional level, with levels of
Comt transcript and protein upregulated in the frontal
cortex of Prodh-deficient mice. This seems to represent
a homeostatic response whereby an increase in Comt
expression is engaged to buffer excessive dopamine
signaling in the frontal cortex of mice with a hypomor-
phic variant of the Prodh gene (Paterlini et al., 2005).
Notably, these animal-model-based predictions
found support in recent studies of individuals with
22q11 microdeletions. These studies revealed that, in
the context of increased L-proline levels, a low-activity
form of the COMT enzyme (Met158) encoded by the non-
deleted allele is a risk factor for the development of
psychotic symptoms in these individuals (Gothelf et al.,
2005; D. Campion et al., 2006, ASHG meeting, abstract).
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ity genes from this locus include knockout mice forComt
(see above) (Huotari et al., 2002, 2004), Zdhhc8 (a palmi-
toyltransferase that plays a key role in the assembly of
excitatory synapses and dendritic growth) (Mukai et al.,
2004), and Tbx1 (a transcription factor) (Paylor et al.,
2006). Apart from PPI assays, systematic analysis of
schizophrenia-related endophenotypes in these mice
has not been reported yet. Among them, heterozygous
mice deficient for the Tbx1 gene were reported to have
robust deficits in PPI (Paylor et al., 2006), but a more re-
cent study failed to observe such deficits (Long et al.,
2006). Interpretation of this finding, if true, is at present
confounded by ample evidence that the Tbx1 gene is
involved in the development of the outer, middle, and
inner ear (Arnold et al., 2006; Vitelli et al., 2003), and ab-
normal PPI is a phenotype expected to emerge as a
result of abnormal ear development (Liu et al., 2000).
A Mouse Model of the DISC1 Schizophrenia/Bipolar
Susceptibility Locus
DISC1 at chromosome 1q42 is one of the leading schizo-
phrenia candidate genes (Gogos and Gerber, 2006;
Porteous and Millar, 2006). DISC1 was originally identi-
fied as the gene interrupted by a balanced translocation
involving chromosomes 1 and 11 (1q42.1;11q14.3)
linked to psychopathology including schizophrenia, de-
pression, and bipolar disorder in a large Scottish family
(Millar et al., 2000). Further association and mutational
studies have been supportive but not unequivocal
(Gogos and Gerber, 2006; Green et al., 2006).
Kamiya et al. (2005) used electroporation of Disc1
RNAi molecules and aDISC1 cDNA encoding for a dom-
inant-negative protein to functionally deplete mouse
Disc1 in utero (E14.5). Postnatally, this manipulation in-
hibited radial neuronal migration in the cerebral cortex
and induced misorientation and shortening of primary
dendrites. This finding appears to be consistent with
in vitro studies, which have shown that DISC1 forms
a complex with NDEL1 and the microtubule-associated
motor protein dynein at the centrosome (Kamiya et al.,
2005; Morris et al., 2003). NDEL1 also binds to LIS1,
a protein involved in lissencephaly (Feng and Walsh,
2004; Shu et al., 2004), a neuronal migration disorder
causing cortical malformation in humans. As a result, it
was suggested that DISC1 is involved in neuronal devel-
opment, particularly within the cerebral cortex, and that
loss of DISC1 function might underlie neurodevelop-
mental dysfunction in schizophrenia and other psychiat-
ric disorders (Sawa and Snyder, 2005). Based on in vitro
observations that phosphodiesterase 4B (PDE4B) and
DISC1 physically interact, Millar et al. (2005) proposed
an alternative model of DISC1 action involving regula-
tion of cAMP signaling, a second messenger system
known to modulate affect and cognition (Duman,
2002). When bound to DISC1, PDE4B is inactivated,
and it is predicted that decreased expression of DISC1
in patients and mice may result in increased PDE activity
and increased inactivation of cAMP.
Koike et al. (2006) attempted to generate an etiologi-
cally valid mouse model by mimicking the putative
effects of the translocation observed in the Scottish
family. They used a gene-targeting approach designed
to generate a truncated Disc1 transcript, and possibly
protein, while at the same time preventing induction ofnonsense-mediated decay and keeping the overall level
of gene expression within physiological range. They
unexpectedly discovered a 25 bp deletion in exon 6 of
the mouse gene in the 129S6/SvEv strain, which induces
a frameshift in the reading frame and results in prema-
ture translational termination. Compared to a variety of
strains, the deletion was specific to 129S6/SvEv, al-
though subsequent analysis found that it is widespread
among many 129 substrains (P.A.A. and J.A.G., unpub-
lished data). Genetic association studies in patients with
schizophrenia and their unaffected siblings suggest that
DISC1 variants might influence working memory perfor-
mance (Callicott et al., 2005; Cannon et al., 2005). Koike
et al. (2006) used Disc1-deficient mice to ask whether
Disc1 deficiency affects spatial working memory perfor-
mance as assessed in a delayed nonmatch to place
task. They found that C57BL/6J mice carrying the genet-
ically modified 129S6/SvEv Disc1 allele (which includes
the exon 6 deletion variant as well as an engineered ter-
mination codon in exon 8 and a polyadenylation signal in
intron 8 [Koike et al., 2006; M. Kvajo, P.A.A., and J.A.G.,
unpublished data]) learned the task and performed as
well as wild-type littermates during training, but during
the working memory test showed a consistent impair-
ment. This deficit was observed in both heterozygous
and homozygous mutant mice, although neither showed
any changes in locomotor activity or PPI (Koike et al.,
2006). Importantly, for the studies outlined above, the
mutant Disc1 allele had to be transferred onto a
C57BL/6J genetic background. While this experimental
design decreases the probability of contribution in trans
of unrelated background genes, it does not address the
well-known ‘‘flanking gene problem’’ (Crusio, 2004),
thus limiting somewhat the etiological validity of the
model in its current form.
It is worth noting that, despite predictions, preliminary
analysis of this mouse model by low-resolution histol-
ogy (Koike et al., 2006) did not reveal the type of changes
in brain morphology anticipated by impaired Ndel1 or
Lis1 function (Feng and Walsh, 2004; Shu et al., 2004).
The reason for this discrepancy is unclear. Apart from
obvious experimental differences and the fact that
some isoforms persist in the Disc1-deficient C57BL/6J
mice (Koike et al., 2006; Kvajo, P.A.A., and J.A.G., un-
published data), it could be that under physiological
conditions Disc1 deficiency results in subtle effects in
neuronal development and migration undetectable by
Nissl staining. It is also possible that under physiological
conditions, in the absence of Disc1, migration is merely
delayed and by adulthood any deficits have been over-
come, with all neurons eventually reaching their final
destination. Such delayed radial migratory processes
may lead to abnormal cortico-cortical connections,
indicating that further analyses at the synaptic and elec-
trophysiological levels are needed.
Limitations and Challenges in Interpreting Findings
from Genetic Models
Despite their obvious advantages, interpreting results
from even the most reliable genetic mouse models
with etiological validity can be confounded by at least
two factors. First, an ideal one-to-one correspondence
between a gene and a modeled endophenotype is un-
likely to exist. More likely, one susceptibility gene
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(A) The relationship between modeled risk genes and modeled endophenotypes is relatively complex, with multiple genes converging on single
modeled endophenotypes and pleiotropic effects of single genes on multiple endophenotypes.
(B) The effect of targeting a risk gene will vary because different genes may have different effect sizes and thus penetrate at different levels of
analysis. With multiple genetic and/or environmental manipulations, the penetrance may be increased such that the animal model will exhibit
various behavioral abnormalities that may approach the clinical syndrome.
(C) An example of a gene3 gene interaction whereby the effect of a targeted gene is buffered by homeostatic mechanisms. These compensatory
processes are modulated by another gene such that if this gene is disrupted, the penetrance of the primary targeted gene effect will increase to
a higher level.affects more than one (but not all) modeled endopheno-
types, and in turn each modeled endophenotype is af-
fected by more than one predisposing gene (Figure 2A).
Therefore, as already evident in the accumulating empir-
ical data outlined in the previous section, a gene-based
model is unlikely to exhibit abnormalities in all schizo-
phrenia-related endophenotypes, and it is expected to
recapitulate fewer features of the disorder as compared,
for example, to models of pathophysiology and patho-
genesis, which are downstream of multiple predispos-
ing genes and thus may affect multiple neural systems
and circuits. Second, genetic manipulations are the
most upstream from the observed clinical psychopa-
thology and thus, in the context of a model nervous sys-
tem, may not manifest at the behavioral level and may
require multiple manipulations to become fully pene-
trant at this level (Figure 2B). This is important because
the effects of a given genetic mutation on a biological
trait can be masked by one or more other genetic or en-
vironmental factor, and as a result, substantial effects on
the phenotype are observed only when there are multi-
ple hits to a disease-related gene network (this phenom-
enon is also known as epistasis) (Moore, 2005). The ef-
fect of a modeled gene may be penetrant only at the
level of synaptic transmission if, for example, efficienthomeostatic responses emerge at higher levels, in the
form of ‘‘damage control’’ (Figure 2C). Such buffering
processes usually depend on well-orchestrated
changes in activity and expression of other genes. In
this case, the full effect of a genetic disruption may
only be revealed in the presence of genetic or pharma-
cological inactivation of these genes (Paterlini et al.,
2005), or in the presence of environmental factors that
compromise the efficiency of genomic buffering. In all,
no single gene model is likely to emerge as representa-
tive of the entire disorder, and at best it will reproduce
either a subtype of the disorder or a particular aspect
of an endophenotype. Elegant, but likely partial, solu-
tions to overcome these limitations can be explored by
combined modeling of more than one genetic risk factor.
This is the case, for example, for mice carrying the
equivalent of the 22q11 microdeletion. It can also be
achieved by crossing more than one engineered mouse
strain or by employing multiple gene knockdowns using
recently developed RNA interference approaches (Yu
and McMahon, 2006). Combined modeling of genetic
deficits and environmental influences such as viral infec-
tions (Shi et al., 2003) or cannabis exposure (Caspi et al.,
2005) offers additional promising solutions in increasing
the power and usefulness of genetic mouse models.
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192Finally, it is worth noting that our argument thus far in
favor of ‘‘etiologically valid’’ genetic mouse models is
based on the assumption that generation of genetic
mouse models of psychiatric disorders follows unequiv-
ocal genetic risk variant identification via human genetic
approaches. This will be the case for some genes, but it
is also likely that for other genes, even under the best of
circumstances (e.g., large patient samples and large
numbers of markers [Scolnick, 2006]), the results will re-
main inconclusive. Such is the ‘‘nature of the beast,’’ that
the combined phenotypic and genetic heterogeneity of
these disorders often limits the power of genetic associ-
ation studies (Freimer and Sabatti, 2004). Even in this
case, however, generation of accurate genetic mouse
models is not without its merits and could be instrumen-
tal in balancing statistical genetic findings from human
studies and hard biological evidence from mouse
studies to establish the ‘‘biological plausibility’’ of puta-
tive etiological factors. Thus, as better-defined ‘‘blue-
prints’’ for the standardized and systematic assessment
of modeled endophenotypes become available, the
boundary between human genetic and animal model
studies is likely to be blurred. Animal models will not
only be imperative in validating and understanding the
contribution of susceptibility genes but also in identify-
ing new ones.
Concluding Remarks
Modeling psychiatric disorders in mice is an evolving
process that has reached a turning point such that accu-
rate mouse models of candidate susceptibility genes are
now becoming feasible. Despite caveats, in the next few
years, etiologically valid genetic models are poised to
offer breakthroughs in our understanding of the patho-
genesis of these disorders. Realization of this promise
will depend on at least three important factors: first, on
the careful dissection of the underlying genetic com-
plexity of the human disorders; second, on the careful
integration of the accumulating genetic findings and
the large volume of data obtained by many years of
work on models of pathophysiology and pathogenesis
and by many years of clinical research, including rapidly
evolving noninvasive brain imaging; and third, on the
broadening and refining of our analytical tools for animal
models.
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